Edwards LifesciencesXSWX:EW +0.37%97 ROC (Joel Greenblatt) % is 77.51% as of Mar. 2026, which is 16% above its 10-year median of 66.82. GuruFocus rates XSWX:EW with a GF Score™ of 97/100 and a GF Value™ of CHF75.73. The stock has 5 warning signs investors should review. Among 841 Medical Devices & Instruments companies, Edwards Lifesciences ranks better than 90.49% on this metric.
Joel Greenblatt defined Return on Capital differently in his book The Little Book That Still Beats the Market (Little Books. Big Profits). He defines ROC (Joel Greenblatt) % as EBIT divided by the total of Property, Plant and Equipment and net working capital. Edwards Lifesciences's annualized ROC (Joel Greenblatt) % for the quarter that ended in Mar. 2026 was 77.51%.
The historical rank and industry rank for Edwards Lifesciences's ROC (Joel Greenblatt) % or its related term are showing as below:
XSWX:EW'
s ROC (Joel Greenblatt) % Range Over the Past 10 Years
Min: 47.85 Med: 66.82 Max: 106.02
Current: 52.6
During the past 13 years, Edwards Lifesciences's highest ROC (Joel Greenblatt) % was 106.02%. The lowest was 47.85%. And the median was 66.82%.
XSWX:EW's ROC (Joel Greenblatt) % is ranked better than 90.49% of 841
companies
in the Medical Devices & Instruments industry
Industry Median: 4.13
vs XSWX:EW: 52.60
Edwards Lifesciences's 5-Year average Growth Rate of ROC (Joel Greenblatt) % was -1.40% per year.
The way Joel Greenblatt defines Return on Capital is a more accurate measure of how efficiently the company generates returns onthe capital actually invested in the business. EBIT is used instead of net income because the tax and interest payment may be affected by factors other than the core business operation. Intangible assets are not included in the calculation because they don't need to be replaced.
Edwards Lifesciences ROC (Joel Greenblatt) % Related Terms
Edwards Lifesciences ROC (Joel Greenblatt) % Historical Data
* Premium members only.
The historical data trend for Edwards Lifesciences's ROC (Joel Greenblatt) % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
XSWX:EW vs DXCM, GEHC, BSX: ROC (Joel Greenblatt) % Comparison
For the Medical Devices subindustry, Edwards Lifesciences's ROC (Joel Greenblatt) %, along with its competitors' market caps and ROC (Joel Greenblatt) % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Edwards Lifesciences ROC (Joel Greenblatt) % vs Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, Edwards Lifesciences's ROC (Joel Greenblatt) % distribution charts can be found below:
* The bar in red indicates where Edwards Lifesciences's ROC (Joel Greenblatt) % falls into.
Joel Greenblatt defined Return on Capital differently in his book The Little Book That Still Beats the Market (Little Books. Big Profits) . He defines Return on Capital as follows:
EBIT stands for Earnings Before Interest and Taxes.
Fixed Assets are also known as non-current assets. They include the Property, Plant and Equipment that the firm needs in its operation.
GuruFocus calculates net working capital as: (Accounts Receivable + Total Inventories + Other Current Assets) - (Accounts Payable & Accrued Expense + Deferred Revenue + Other Current Liabilities). We're trying to account for OPERATING assets and liabilities (part of daily business) when calculating working capital. Cash and marketable securities are considered NON-OPERATING assets and are not included in calculation. We will also back out all interest bearing debt, short term debt and the portion of long term debt that is due in the current period from the current liabilities. This debt will be considered when computing cost of capital and it would be inappropriate to count it twice.
Note:
The EBIT data used here is four times the quarterly (Mar. 2026) EBIT data.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
What does a ROC (Joel Greenblatt) % of 77.51% mean?
Edwards Lifesciences (XSWX:EW) has a ROC (Joel Greenblatt) % of 77.51% as of Mar. 2026. Joel Greenblatt's return on capital is the ratio of EBIT to average fixed assets and net working capital. View historical data on Edwards Lifesciences and its competitors. This is 16% above median its historical median of 66.82. Over the past decade, Edwards Lifesciences' ROC (Joel Greenblatt) % has ranged from 47.85 to 106.02. According to the industry distribution chart, Edwards Lifesciences ranks #80 out of 841 companies in the Medical Devices & Instruments industry, placing it in the top 9.5%.
Is Edwards Lifesciences' ROC (Joel Greenblatt) % too high?
Edwards Lifesciences' current ROC (Joel Greenblatt) % of 77.51% is 16% above median its 10-year median of 66.82. Over the past 10 years, this metric has ranged from a low of 47.85 to a high of 106.02. The Medical Devices & Instruments industry median ROC (Joel Greenblatt) % is 4.13. Edwards Lifesciences' value of 77.51% is 1776.8% above this industry median. Based on the distribution chart, Edwards Lifesciences ranks #80 out of 841 companies in the Medical Devices & Instruments industry, which is in the top quartile — a strong position relative to peers. Overall, Edwards Lifesciences has a GF Score™ of 97/100, reflecting its overall financial health beyond just this single metric.
How does Edwards Lifesciences' ROC (Joel Greenblatt) % compare to DXCM and GEHC?
According to the Medical Devices & Instruments industry distribution chart, Edwards Lifesciences ranks #80 out of 841 companies for ROC (Joel Greenblatt) %. This places Edwards Lifesciences in the top 10% of its industry — outperforming the majority of peers. The industry median ROC (Joel Greenblatt) % is 4.13. Edwards Lifesciences' value of 77.51% is 1776.8% above this benchmark. Historically, Edwards Lifesciences' own ROC (Joel Greenblatt) % has ranged from 47.85 to 106.02 over the past decade. While the company's 10-year median is 66.82 vs. the industry median of 4.13, Edwards Lifesciences has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good ROC (Joel Greenblatt) % for a Medical Devices & Instruments company?
The median ROC (Joel Greenblatt) % among Medical Devices & Instruments companies is 4.13, based on 841 companies in the industry. Companies in the top quartile (top 25%) have a ROC (Joel Greenblatt) % significantly above this median, while those in the bottom quartile fall well below. However, ROC (Joel Greenblatt) % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Edwards Lifesciences's current ROC (Joel Greenblatt) % of 77.51% is 1776.8% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high ROC (Joel Greenblatt) % mean?
A high ROC (Joel Greenblatt) % can signal that a stock is expensive relative to its fundamentals. Joel Greenblatt's return on capital is the ratio of EBIT to average fixed assets and net working capital. View historical data on Edwards Lifesciences and its competitors. For the Medical Devices & Instruments industry, the median ROC (Joel Greenblatt) % is 4.13 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Edwards Lifesciences's current ROC (Joel Greenblatt) % is 77.51%, which is 16% above median its own 10-year median of 66.82. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Edwards Lifesciences stock overvalued right now?
Edwards Lifesciences (XSWX:EW) has a current ROC (Joel Greenblatt) % of 77.51%. The stock's GF Value™ is CHF75.73, compared to a current price of CHF72.91 — trading 3.7% below its estimated fair value. The current ROC (Joel Greenblatt) % is 77.51%, which is 16% above median its 10-year median of 66.82 and 1776.8% above the Medical Devices & Instruments industry median of 4.13. Edwards Lifesciences' overall GF Score™ is 97/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is ROC (Joel Greenblatt) % calculated?
ROC (Joel Greenblatt) % is calculated from a company's financial statements. For Edwards Lifesciences (XSWX:EW), the current ROC (Joel Greenblatt) % is 77.51% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Edwards Lifesciences (XSWX:EW) Overvalued in 2026?
Based on GuruFocus' analysis, Edwards Lifesciences stock appears to be undervalued.
The current stock price of CHF72.91 is trading 3.7% below its estimated GF Value™ of CHF75.73.
Key valuation signals for XSWX:EW:
ROC (Joel Greenblatt) %: 77.51% (16% above median its 10-year median of 66.82)
GF Value™: CHF75.73 vs. price of CHF72.91 (3.7% below fair value)
Industry Position: 1776.8% above the Medical Devices & Instruments median (#80 of 841)
No single metric tells the full story. See the XSWX:EW stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Spun off from Baxter International in 2000, Edwards Lifesciences designs, manufactures, and markets a range of medical devices and equipment for advanced stages of structural heart disease. It has established itself as a leader across key products, including surgical tissue heart valves, transcatheter aortic valves, and transcatheter mitral and tricuspid valve technologies. The firm derives about 60% of its total sales from outside the US.
97GF Score
Get the complete analysis for XSWX:EW
ROC (Joel Greenblatt) % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
XSWX:EW has been successfully added to your 
